Stage
Series A | AliveTotal Raised
$7MLast Raised
$7M | 12 yrs agoMissing: Anexon's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Anexon's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Anexon
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Anexon is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Anexon Frequently Asked Questions (FAQ)
Where is Anexon's headquarters?
Anexon's headquarters is located at C/o Healthcare Ventures, Cambridge.
What is Anexon's latest funding round?
Anexon's latest funding round is Series A.
How much did Anexon raise?
Anexon raised a total of $7M.
Who are the investors of Anexon?
Investors of Anexon include Mayo Clinic.
Who are Anexon's competitors?
Competitors of Anexon include Adamas Pharmaceuticals, Neos Therapeutics, Metabolic Solutions Development, Soleno Therapeutics, Cerenis Therapeutics and 12 more.
Compare Anexon to Competitors
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Metabolic Solutions Development Company (MSDC) is a drug discovery and development company investigating new molecular targets and developing therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes.
Orexo is a pharmaceutical company which focuses on identifying suboptimal therapeutic characteristics of existing products and developing more efficient and effective delivery methods for them.
Icagen partners with pharmaceutical and biotechnology companies to offer scientific expertise and access to technologies for ion channel and transporter drug discovery and development. The Icagen team has experience advancing molecules from drug discovery to clinical development across multiple therapeutic areas and ion channel classes. Icagen's tool box comprises a range of cell lines and technologies for ion channel and transporter research, capped by the label-free XRpro platform. XRpro technology, based on X-ray fluorescence, enables high throughput assessment of ion channels and transporters, including challenging systems with high therapeutic interest.
Intranasal Therapeutics, founded in 1998 by Edwin Cohen, founder and former Chairman and CEO of Barr Laboratories, Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products, with a particular focus on drugs treating pain and disorders related to the central nervous system.
Piedmont is a specialty pharmaceutical company focused on human and animal health therapeutics with expertise in parasitology and drug delivery systems.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.